|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin显示文摘 | Ofer Nativ J. Alfred Witjes Kees Hendricksen Michael Cohen Daniel Kedar Ami Sidi Renzo Colombo Ilan Leibovitch | 2009 | The Journal of Urology2009，，4： | 2 |
| 2 | Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs,treatment schedules,and long-term results显示文摘 | Witjes JA Hendricksen K | 2008 | Eur Urol2008，53，1： | 1 |
| 3 | Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism显示文摘We have recently developed an enzyme-directed immunostimulant(EDI)prodrug motif,which is metabolized to active immunostimulant by cancer cells and,following drug efflux,activates nearby immune cells,resulting in immunogenicity.In this study,we synthesized several EDI prodrugs featuring an imidazoquinoline immunostimulant resiquimod(a Toll-like receptor 7/8 agonist)covalently modified with glycosidase enzyme-directing groups selected from substrates of β-glucuronidase,α-mannosidase,or β-galactosidase.We compared the glycosidase-dependent immunogenicity elicited by each EDI in RAW-Blue macrophages following conversion to active immunostimulant by complementary glycosidase.At a cellular level,we examined EDI metabolism across three cancer cell lines(B16 melanoma,TC2 prostate,and 4T1 breast cancer).Comparing the relative immunogenicity elicited by each EDI/cancer cell combination,we found that B16 cells produced the highest EDI prodrug immunogenicity,achieving>95% of that elicited by unmodified resiquimod,followed by TC2 and 4T1 cells(40% and 30%,respectively).Immunogenicity elicited was comparable for a given cell type and independent of the glycosidase substrate in the EDIs or differences in functional glycosidase activity between cell lines.Measuring drug efflux of the immunostimulant payload and efflux protein expression revealed that EDI/cancer cell-mediated immunogenicity was governed by efflux potential of the cancer cells.We determined that,following EDI conversion,immunostimulant efflux occurred through both P-glycoprotein-dependent and P-glycoprotein-independent transport mechanisms.Overall,this study highlights the broad ability of EDIs to couple immunogenicity to the metabolism of many cancers that exhibit drug efflux and suggests that designing future generations of EDIs with immunostimulant payloads that are optimized for drug efflux could be particularly beneficial. | Austin T Ryan Anunay J Pulukuri Maryam Davaritouchaee Armina Abbasi Aaron T Hendricksen Larissa K Opp Anthony J Burt Amy E Nielsen Rock J Mancini | 2020 | Acta Pharmacologica Sinica2020，41，7： | 1 |
| 4 | Compari- son of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer显示文摘 | HENDRICKSEN K WITJES WP IDEMA JG ct al | 2008 | Eur Urol2008，53，5： | 1 |
| 5 | Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer显示文摘 | Hendricksen K Cornel EB de Reijke TM | 2012 | J Urol2012，187，4： | 1 |
| 6 | Hydrofluoric Acid Stimulation of Sandstone Reservoirs 显示文摘 | Smith C F and Hendricksen A R | 1965 | JPT1965，1965，： | 1 |
| 7 | Intravesical hy- perthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party 显示文摘 | Alfred Witjes J Hendricksen K Gofrit O | 2009 | World J Urol2009，27，3： | 1 |
| 8 | Invesical pharmacotherapy for non-muscle-invasive bladder cancer= a critical analysis of currently available drugs, treatment schedules, anti long- term results显示文摘 | Witjes JA Hendricksen K | 2008 | Eur Urol2008，53，47： | 1 |
| 9 | Intravesical pharmacotherapy for nonmuscle-invasive bladder cancer:a critical analysis of currently available drugs,treatment schedules,and long-term results显示文摘 | Witjes JA Hendricksen K | 2008 | Eur Uro12008，53，： | 1 |
| 10 | CombinedThermo- Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin 显示文摘 | Nativ O Witjes J A Hendricksen K | 2009 | J Urology2009，182，4： | 1 |
| 11 | Potential and toxicity of intravesical pemetrexed : a preclinical study in pigs 显示文摘 | Hendricksen K Moonen PM van der Heijden AG | 2006 | Clin Cancer Res2006，12，： | 1 |
| 12 | Intravesical pharmacotherapy for non muscle invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long term results 显示文摘 | Witjes J A Hendricksen k | 2008 | Enr Urol2008，53，1： | 1 |
| 13 | Potential and toxicity of intravesical pemetrexed : a preclinical study in pigs显示文摘 | Hendricksen K Moonen PM van derHeijden AG | 2006 | Clin Cancer Res2006，12，： | 1 |
| 14 | Intravesical Pharmacotherapy for Non–Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results 显示文摘 | J. Alfred Witjes Kees Hendricksen | 2007 | European Urology2007，，1： | 1 |
| 15 | Combined thermo- chemotherapy for recurrent bladder cancer after bacillus Calmette- Guerin 显示文摘 | Nativ O Witjes J A Hendricksen K | 2009 | The Journal of urology2009，182，4： | 1 |
| 16 | Intravesical gemcitabine:an update of clinical results显示文摘 | Hendricksen K Witjes JA | 2006 | Curr Opin Urol2006，16，： | 1 |
| 17 | Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer显示文摘 | Lammers RJ Witjes WP Hendricksen K | 2011 | Eur Urol2011，60，4： | 1 |
| 18 | Smoking status is a risk factor for recurrence aider transurethral resection of non-musele-invasive bladder cancer显示文摘 | Lammers R J Witjes WP Hendricksen K | 2011 | Eur Urol2011，60，4： | 1 |
| 19 | Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer显示文摘 | Hendricksen K Cornel EB de Reijke TM | 2012 | J Urol2012，187，： | 1 |
| 20 | Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer显示文摘 | LAMMERS RJ WITJES WP HENDRICKSEN K | 2011 | Eur Urol2011，60，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员